Bicara Therapeutics (BCAX) Wells Fargo 20th Annual Healthcare Conference 2025 summary

Key clinical developments and trial updates

• Lead asset is an EGFR TGF-beta bifunctional, showing significant improvement in overall survival for head and neck cancer, with median OS of 21.3 months versus 12.3 months for standard care at ASCO presentation.

• Registrational FORTIFY-HN01 trial initiated in January, actively enrolling, with key readouts expected over the next couple of years.

• Dose optimization ongoing under FDA Project Optimus, comparing 750 mg and 1,500 mg doses; 750 mg data to be presented late this year or early next.

• Additional cohorts exploring alternative dosing schedules, with data expected in the first half of next year.

• Expansion into locally advanced head and neck cancer and colorectal cancer, with new trials planned or starting soon.

Mechanism of action and efficacy insights

• EGFR and TGF-beta pairing aims to overcome resistance and enhance synergy with PD-1 inhibitors like pembro.

• Confirmed response rate of 54% and duration of response of 21.7 months, nearly tripling the responder population compared to pembro monotherapy.

• Similar high response rates observed regardless of CPS score, differentiating from historical controls.

• Activity in both HPV-positive and HPV-negative patients, but pivotal trial focuses on HPV-negative due to greater expected benefit.

• TGF-beta component shown to recapture responses in colorectal cancer patients previously treated with EGFR therapies.

Safety and patient management

• Main EGFR-related adverse event is acneiform rash, managed similarly to cetuximab protocols.

• TGF-beta-related anemia is manageable with oral iron, with no discontinuations or dose reductions required.

• Some transient, low-grade bleeding events observed, but these do not require treatment interruption.